The DPP-4 inhibitors diprotin A, FFA-free Bovine Serum Albumine (BSA), Chenodeoxycholic acid (CDCA), TβMCA, Exendin-4(9-39), Phloretin, DMSO and CMC were purchased from Sigma-Aldrich (St Quentin-Fallavier, France). Sitagliptin was purchased from MSD. The synthetic FXR agonist GW4064 was purchased from Tocris (R&D Systems, Lille, France). For in vitro or ex vivo experiments, CDCA, TβMCA and GW4064 were dissolved in dimethylsulfoxide (DMSO) at 0.1% final. For in vivo experiments, GW4064 was dissolved in 1% Carboxymethylcellulose (CMC) and Exendin-4(9-39) was dissolved in NaCl 0.9%. Chow and high fat diets were purchased from UAR (A04, Villemoison/Orge, France). Colesevelam HCl was a kind gift of Daiichi Sankyo.
Sitagliptin
Manufactured by MSD
Sourced in China, Poland
Sitagliptin is a lab equipment product manufactured by MSD. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is a type of enzyme involved in the regulation of blood sugar levels.
Automatically generated - may contain errors
Lab products found in correlation
Chenodeoxycholic acid, by Merck Group (2 mentions)
Phloretin, by Merck Group (2 mentions)
Diprotin a, by Merck Group (2 mentions)
Ffa free bovine serum albumine, by Merck Group (2 mentions)
Tβmca, by Merck Group (2 mentions)
Exendin 4 9 39, by Merck Group (2 mentions)
Gw4064, by R&D Systems (2 mentions)
Dimethyl sulfoxide (dmso), by Merck Group (2 mentions)
Apidra, by Sanofi (1 mentions)
Galvus, by Novartis (1 mentions)
Lantus, by Sanofi (1 mentions)
4 protocols using sitagliptin
1
Pharmacological Modulators of Bile Acid Signaling
2
Insulin Therapy for Glycemic Control
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
During the run‐in period, participants were hospitalized, and stopped previous OADs except for MET (no changed dosage), then received short‐term intensive insulin therapy with Gla (Lantus; Sanofi) and bolus insulin glulisine (Apidra; Sanofi). All participants who had an FPG of less than 7.0 mmol/L and 2‐hour postprandial glucose (PPG) of less than 10.0 mmol/L in the last 2 consecutive days of the run‐in period were discharged from hospital and randomly assigned (1:1) to receive once‐daily basal insulin glargine in combination with a dipeptidyl peptidase‐4 inhibitor (DPP4i; either sitagliptin [Januvia; MSD, Beijing, China] or vildagliptin [Galvus; Novartis, Beijing, China]) or twice‐daily premixed insulin aspart (Asp30; Novolog Mix 70/30; Novo Nordisk, Tianjin, China). All participants continued to receive their background MET. Randomization was performed using centralized interactive response technology and was stratified by baseline sulphonylurea/glinide use and HbA1c level at screening (>9.0% or ≤9.0% [>75 or ≤75 mmol/mol]). While participants, investigators and site staff remained unmasked to treatment, the statistician and sponsor were masked to the treatment assignment until after database lock and completion of analyses.
3
Pharmacological Modulators of Bile Acid Signaling
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The DPP-4 inhibitors diprotin A, FFA-free Bovine Serum Albumine (BSA), Chenodeoxycholic acid (CDCA), TβMCA, Exendin-4(9-39), Phloretin, DMSO and CMC were purchased from Sigma-Aldrich (St Quentin-Fallavier, France). Sitagliptin was purchased from MSD. The synthetic FXR agonist GW4064 was purchased from Tocris (R&D Systems, Lille, France). For in vitro or ex vivo experiments, CDCA, TβMCA and GW4064 were dissolved in dimethylsulfoxide (DMSO) at 0.1% final. For in vivo experiments, GW4064 was dissolved in 1% Carboxymethylcellulose (CMC) and Exendin-4(9-39) was dissolved in NaCl 0.9%. Chow and high fat diets were purchased from UAR (A04, Villemoison/Orge, France). Colesevelam HCl was a kind gift of Daiichi Sankyo.
4
Pharmacological agents for animal studies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Sitagliptin (Januvia—tablets 100 mg) was purchased from MSD (Warsaw, Poland), heparin (Heparinum WZF—ampoules 25,000 U/5 mL) from Polfa Warszawa (Warsaw, Poland), ketamine hydrochloride (Bio-ketan) from Vetoquinol Biowet (Gorzów Wlkp, Poland), medetomidine hydrochloride (Domitor, ampoules 1 mg/mL) from Orion Pharma (Warsaw, Poland), butorphanol tartrate (Morphasol, ampoules 4 mg/mL) from aniMedica GmbH (Frankfurt am Main, Germany), Ringer solution from Polfa Lublin S.A. (Lublin, Poland), and solution of 0.9% sodium chloride was obtained from Polpharma S.A. (Starogard Gdański, Poland).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!